We’re committed to bringing effective and reliable medicines to patients. Our research helps us better understand disease. It allows us to test and develop new medicines. It lets us teach people more about their disease and treatment options.
We are dedicated to improving the lives of patients through developing and providing access to new treatments.
Our research focuses on serious diseases.
Some areas we are working on are:
When we create new medicines to help patients, we put science and innovation first. We work with some of the world’s top institutes, who share our vision.
By exploring new treatment areas, we can help even more people.
This will help us create new treatments that could change medical care. It will help us make a difference for patients. Most importantly, it will help us inspire hope in those who need it most.
This section will help you find trials that may be right for you.
Learn more about them below:
Adults with newly diagnosed acute myeloid leukemia or AMLGo
A study of ASP4345 as add-on treatment in patients with SchizophreniaGo
A study for women with moderate to severe vasomotor symptoms (hot flashes) associated with menopauseGo
A study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)Go
A study of IMAB362 plus mFOLFOX6 in patients with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) CancerGo
A study of ASP8374, an Immune Checkpoint Inhibitor, in patients with Advanced Solid TumorGo
Listed below are some current key areas of research. To learn about other Astellas trials seeking participants, visit ClinicalTrials.gov
Astellas is committed to sharing the results of our clinical trials. This is important to help advance science and better help patients. It is also the best way to tell health care providers and patients about scientific findings relating to our medicines.Learn about results of Astellas clinical trials
To learn more about disclosure and to read our full policy, click here.